Business
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 millionFunding award milestone follows Daré's announcement last week of the initiation of its Phase 2 clinical study of DARE-HPV — representing the first time women with persistent high-risk HPV infection may have access to this pharmacologic treatment as part of a clinical trialDARE-HPV targets high-risk HPV infection, the cause of virtually all cervical cancer cases in t
About this update from Dare Bioscience, Inc.
[{"type":"image","alt":"Daré Bioscience, Inc.","displaySize":"","headline":null,"caption":"Daré Bioscience, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/b3330a5ea5a04281ef6459cd3df6a853"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/d0Q6BxIcwkh3NEWtzlz17g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MA--/https://media.zenfs.com/en/globenewswire.com/b3330a5ea5a04281ef6459cd3df6a853","width":300,"height":114},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/d0Q6BxIcwkh3NEWtzlz17g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MA--/https://media.zenfs.com/en/globenewswire.com/b3330a5ea5a04281ef6459cd3df6a853","width":300,"height":114}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 million","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"Funding award milestone follows Daré's announcement last week of the initiation of its Phase 2 clinical study of DARE-HPV — representing the first time women with persistent high-risk HPV infection may have access to this pharmacologic treatment as part of a clinical trial","length":277,"tagName":"p"}]},{"val":[{"type":"text","content":"DARE-HPV targets high-risk HPV infection, the cause of virtually all cervical cancer cases in the U.S., for which there are currently no FDA-approved pharmacologic treatments","length":174,"tagName":"p"}]},{"val":[{"type":"text","content":"Award reflects Daré's strategy of leveraging non-dilutive government funding, including both NIH grants and ARPA-H contract support for DARE-HPV, to advance a differentiated pipeline addressing some of the most persistent unmet needs in women's health","length":259,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":842,"olType":false},{"type":"text","content":"SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced receipt of a Notice of Award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), obligating the se...